Synageva BioPharma (GEVA +0.9%) says the first patient has been initiated treatment in its Phase...

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Synageva BioPharma (GEVA +0.9%) says the first patient has been initiated treatment in its Phase 3 study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency. Once fully initiated, the trial will enroll 50 child and adult patients with late onset LAL Deficiency.